Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. SPRIX is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at the opioid level. OXAYDO, the first and only approved immediate-release oxycodone product formulated to discourage abuse via snorting, is approved in the United States for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. Both products are approved by the U.S. Food and Drug Administration, but only SPRIX is commercially available at this time.

To support the commercialization of both products, Egalet has made progress developing and augmenting the company's commercial capabilities. Since the acquisition of both products in early January of this year, Egalet has:

  • Hired Deanne Melloy as chief commercial officer, who has significant experience marketing pain products;
  • Established programs to support the promotion of SPRIX including:
    • Transitioned SPRIX from Luitpold Pharmaceuticals;
    • Began promotional activities in the first quarter;
    • Created SPRIX Direct, a specialty pharmacy distribution program, to make access easier for patients needing SPRIX; and
    • Informed over 8,500 prescribers regarding how to obtain SPRIX via SPRIX Direct.
  • Prepared for the commercial launch of OXAYDO in the third quarter of 2015 by:
    • Developing promotional materials and launch plan activities;
    • Creating a multi-channel distribution model; and
    • Establishing a market access strategy for OXAYDO.
  • Began building market access capabilities and hired Tim Cochran as vice president of sales and market access who has extensive pain sales experience;
  • Enhanced medical affairs capabilities with the hiring of Wendy Niebler as senior vice president, clinical development and medical affairs and Donna Zarycranski as executive director of medical affairs operations;
  • Created selection criteria for the hiring of regional managers expected to occur in the second quarter;
  • Developed target profiles for a 50- to 60-person specialty sales group, with intentions to have them trained and in the field by the third quarter; and
  • Outlined a key opinion leader plan to further engage with thought leaders in the pain space.

"The first half of the year is about putting our systems in place to support the launch of commercial promotion, including sales specialists, of both SPRIX and OXAYDO, which is expected to begin in the third quarter," said Bob Radie, Egalet's president and chief executive officer. "We look forward to increasing the awareness of SPRIX and OXAYDO to healthcare providers and patients."

SOURCE Egalet Corporation


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
N95 respirators potential standard of care in nursing homes and healthcare settings during respiratory viral infections